(MEMPHIS, Tenn. – November 30, 2023) Immunotherapy using modified chimeric antigen receptor (CAR) T cells has greatly improved survival rates for pediatric patients with relapsed and recurrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results